Want to see JP:4461 full AI Analyst Report?
4461 Stock Chart & Stats
¥8230.00
-¥60.00(-1.64%)
At close: 4:00 PM EST
¥8230.00
-¥60.00(-1.64%)
Day’s Range― - ―
52-Week Range¥4,935.00 - ¥13,540.00
Previous CloseN/A
Volume29.40K
Average Volume (3M)144.71K
Market Cap
¥133.54B
Enterprise Value¥142.66K
Total Cash (Recent Filing)¥21.06B
Total Debt (Recent Filing)¥27.44B
Price to Earnings (P/E)15.9
Beta1.67
Next Earnings
Nov 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.19%
Share Statistics
EPS (TTM)792.35
Shares Outstanding10,684,321
10 Day Avg. Volume174,660
30 Day Avg. Volume144,713
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.45
Price to Sales (P/S)0.91
P/FCF Ratio11.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)612.6
Revenue Forecast (FY)¥87.00B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthDebt-to-equity falling to ~0.56 and a sizable equity build indicate improved financial flexibility and a stronger cushion against downturns. This lower leverage supports sustainable investment, reduces refinancing risk, and gives management room to pursue growth without immediate pressure on cash flows.
Revenue & Margin RecoveryA return to double-digit revenue growth and margin expansion in 2026 reflects improving pricing, mix, and operating leverage. Sustained top-line momentum with expanding gross and operating margins supports through-cycle profitability and enhances the company's ability to fund capex and returns to shareholders.
Free Cash Flow QualityConsistent positive FCF in 2025–2026 and strong conversion (64–72% of net income) indicate earnings are translating into real cash. This supports deleveraging, reinvestment, and shareholder returns and signals improved earnings quality versus prior periods with weak cash flow.
Bears Say
Earnings VolatilityHistoric swings including a 2023 loss show the business can suffer severe earnings volatility. Such variability reduces predictability of returns, complicates capital allocation, and increases the chance of leverage re-expansion if a downturn undermines margins or revenue.
Debt Load RiskAlthough leverage has improved, ~¥29B of debt is sizable relative to the business. In a prolonged slowdown or margin reversion the company could re-leverage, increasing interest burden and constraining strategic options; meaningful absolute debt raises refinancing and covenant risk.
Cash Conversion SensitivityOperating cash flow has been modest relative to revenue and inconsistent historically, reflecting sensitivity to working capital and investment cycles. This uneven cash conversion can force external funding during stress, limiting resilience and making free cash flow less reliable for long-term planning.
DKS Co., Ltd. News
4461 FAQ
What was DKS Co., Ltd.’s price range in the past 12 months?
DKS Co., Ltd. lowest stock price was ¥4935.00 and its highest was ¥13540.00 in the past 12 months.
What is DKS Co., Ltd.’s market cap?
DKS Co., Ltd.’s market cap is ¥133.54B.
When is DKS Co., Ltd.’s upcoming earnings report date?
DKS Co., Ltd.’s upcoming earnings report date is Nov 04, 2026 which is in 93 days.
How were DKS Co., Ltd.’s earnings last quarter?
DKS Co., Ltd. released its earnings results on Jul 29, 2026. The company reported ¥293.7 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is DKS Co., Ltd. overvalued?
According to Wall Street analysts DKS Co., Ltd.’s price is currently Overvalued.
Does DKS Co., Ltd. pay dividends?
DKS Co., Ltd. pays a Semiannually dividend of ¥75 which represents an annual dividend yield of 1.19%. See more information on DKS Co., Ltd. dividends here
What is DKS Co., Ltd.’s EPS estimate?
DKS Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does DKS Co., Ltd. have?
DKS Co., Ltd. has 10,684,321 shares outstanding.
What happened to DKS Co., Ltd.’s price movement after its last earnings report?
DKS Co., Ltd. reported an EPS of ¥293.7 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.106%.
Which hedge fund is a major shareholder of DKS Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4461
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DKS Co., Ltd.
Headquartered in Kyoto, Japan, DKS Co. Ltd. is a global producer and purveyor of a diverse range of industrial chemicals and surfactants, serving numerous industries worldwide. The company’s operations are organized into six distinct segments: Surfactants, Amenity Materials, Polyurethane Materials, Functional Materials, Electronic Device Materials, and Life Sciences. Within its Surfactants division, DKS develops various types such as nonionic, anionic, cationic, polymerizable, and amphoteric compounds, in addition to specialized surfactant blends. The Amenity Materials segment features products like sucrose fatty acid esters, sodium carboxymethyl celluloses, cellulose nanofibers and other polymers, polyvinyl pyrrolidone, polyacrylamide and polyacrylate, and industrial deodorizers. Its Polyurethane Materials offerings include polyether polyols, urethane prepolymers, and comprehensive urethane systems. For Functional Materials, DKS manufactures radiation-curable monomers and oligomers, waterborne polyurethanes, flame retardants, and amide-based lubricants. The Electronic Device Materials group supplies ionic liquids, ion-conductive polymers, ceramic/metal injection molding components, conductive pastes for electronic applications, injection molding pellets, and advanced inorganic materials. Furthermore, the Life Sciences segment crafts health and dietary supplements, notably an I. Japonica-Bombyx Fungus product and Sudachin, a distinct citrus peel extract powder. Founded in 1909, the firm was formerly known as Dai-ichi Kogyo Seiyaku Co., Ltd. before rebranding to DKS Co. Ltd. in 2013.
Technical Analysis
T Hasegawa Co
―
Sanyo Chemical Industries
―
Tri Chemical Laboratories Inc.
―
Takasago International Corporation
―
MEC Company Ltd.
―